ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy
- PMID: 32449975
- DOI: 10.1002/humu.24056
ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy (VSports手机版)
Abstract
Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy are a spectrum of rare lysosomal storage disorders characterized by acid ceramidase deficiency (ACD), resulting from pathogenic variants in N-acylsphingosine amidohydrolase 1 (ASAH1). Other than simple listings provided in literature reviews, a curated, comprehensive list of ASAH1 mutations associated with ACD clinical phenotypes has not yet been published. This publication includes mutations in ASAH1 collected through the Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NHS), ClinicalTrials. gov identifier NCT03233841, in combination with an up-to-date curated list of published mutations. The NHS is the first to collect retrospective and prospective data on living and deceased patients with ACD presenting as Farber disease, who had or had not undergone hematopoietic stem cell transplantation. Forty-five patients representing the known clinical spectrum of Farber disease (living patients aged 1-28 years) were enrolled. The curation of known ASAH1 pathogenic variants using a single reference transcript includes 10 previously unpublished from the NHS and 63 that were previously reported. The publication of ASAH1 variants will be greatly beneficial to patients undergoing genetic testing in the future by providing a significantly expanded reference list of disease-causing variants. VSports手机版.
Keywords: ASAH1; Farber disease; N-acylsphingosine amidohydrolase 1; acid ceramidase; acid ceramidase deficiency (ACD); lysosomal storage disorder; spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) V体育安卓版. .
© 2020 Wiley Periodicals LLC.
References
REFERENCES
-
- Alayoubi, A. M., Wang, J. C., Au, B. C., Carpentier, S., Garcia, V., Dworski, S., … Medin, J. A. (2013). Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Molecular Medicine, 5, 827-842.
-
- Alves, M. Q., Le Trionnaire, E., Ribeiro, I., Carpentier, S., Harzer, K., Levade, T., & Ribeiro, M. G. (2013). Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene. Molecular Genetics and Metabolism, 109, 276-281.
-
- Antonarakis, S. E., Valle, D., Moser, H. W., Moser, A., Qualman, S. J., & Zinkham, W. H. (1984). Phenotypic variability in siblings with Farber disease. Journal of Pediatrics, 104, 406-409.
-
- Bedia, C., Camacho, L., Abad, J. L., Fabrias, G., & Levade, T. (2010). A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease. Journal of Lipid Research, 51, 3542-3547.
-
- van der Beek, N. A., Nelson, I., Froissart, R., Levade, T., Garcia, V., Lacene, E., … Behin, A. (2019). A new case of SMA phenotype without epilepsy due to biallelic variants in ASAH1. European Journal of Human Genetics, 27, 337-339.
"VSports手机版" Publication types
- "V体育官网" Actions
MeSH terms
- VSports app下载 - Actions
- "VSports注册入口" Actions
- "VSports手机版" Actions
- VSports - Actions
- Actions (V体育安卓版)
- VSports最新版本 - Actions
- "VSports在线直播" Actions
- "V体育ios版" Actions
- Actions (V体育官网入口)
- Actions (V体育ios版)
- "VSports注册入口" Actions
Substances
Associated data
- "V体育2025版" Actions
LinkOut - more resources
Full Text Sources
Medical
Research Materials
